IP Library › Granted Patent US 12,352,761
Granted Patent B2
US 12,352,761 · App. 17/282,150 · Granted Jul 8, 2025

Use of ligands derived from receptor-binding domain of porcine endogenous retrovirus type B for diagnosing SMVT-related diseases

Inventors: Marc Sitbon (Montpellier, FR); Vincent Petit (Paris, FR); Svilena Ivanova (Neuchâtel, CH); Jean-Luc Battini (Montpellier, FR); Valérie Courgnaud (Montpellier, FR); Donatella Giovannini (Montpellier, FR); Jawida Lezaar (Montpellier, FR)
Assignees: METAFORA BIOSYSTEMS; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE; UNIVERSITÉ DE MONTPELLIER; UNIVERSITÉ PARIS CITÉ
G01N33/6872A61K49/00C07K14/08G01N2333/15
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,352,761
App. No.
17/282,150
Granted
Jul 8, 2025
Kind
B2
Abstract

Methods for detecting and/or measuring the level of sodium-dependent multivitamin transporter (SMVT) in a biological sample. The methods include the steps of: (a) contacting the biological sample with a PERV-B.RBD ligand, a variant and/or a fragment thereof; and, detecting and/or measuring the binding of the PERV-B.RBD ligand, variant and/or fragment thereof to SMVT.

Claims (20)

1. An in vitro method for detecting and/or measuring the level of sodium-dependent multivitamin transporter (SMVT) in a biological sample, wherein said method comprises the steps of:

a. contacting said biological sample with a PERV-B.RBD ligand, which is a receptor binding domain (RBD) ligand isolated from an envelope protein of porcine endogenous retrovirus type B (PERV-B), a variant and/or a fragment; and,

b. detecting and/or measuring the binding of said PERV-B.RBD ligand, variant and/or fragment to SMVT,

wherein said PERV-B.RBD ligand comprises a sequence consisting of the sequence SEQ ID NO: 6, a variant and/or fragment,

wherein said variant presents a sequence identity of at least 90% with the sequence SEQ ID NO: 6,

wherein said fragment is a fragment of the sequence SEQ ID NO: 6 or of said variant, and

wherein said variant and/or fragment binds to SMVT.

2. The in vitro method according to claim 1 , wherein said method further comprises comparing the binding level measured at step b. with a reference value.

3. The in vitro method according to claim 1 , wherein the amino acid sequence of said PERV-B.RBD ligand, variant and/or fragment comprises or consists of an amino acid sequence selected from the group consisting of the amino acid sequences SEQ ID NO: 6, SEQ ID NO: 20, SEQ ID NO: 22, variants thereof, and/or fragments thereof.

4. The in vitro method according to claim 1 , wherein said PERV-B.RBD ligand, variant and/or fragment thereof is labeled with a detectable label.

5. The in vitro method according to claim 1 , wherein said method is for diagnosing a SMVT-related disease in a subject or for identifying a subject as being at risk of developing a SMVT-related disease.

6. The in vitro method according to claim 5 , wherein said SMVT-related disease is cancer.

7. The in vitro method according to claim 5 , wherein said SMVT-related disease is a neuroinflammatory disease.

8. The in vitro method according to claim 5 , wherein said SMVT-related disease is a disorder of pregnancy.

9. The in vitro method according to claim 5 , wherein said SMVT-related disease is an infectious disease.

10. The in vitro method according to claim 6 , wherein said cancer is selected from the group consisting of liver cancer, prostate cancer, lung, cancer, gallbladder cancer, pancreas cancer, colon cancer, ovarian cancer, brain cancer, kidney cancer, thyroid cancer and lymphomas.

11. The in vitro method according to claim 7 , wherein said neuroinflammatory disease is multiple sclerosis.

12. The in vitro method according to claim 8 , wherein said disorder of pregnancy is pre-eclampsia or intrauterine growth retardation.

13. The in vitro method according to claim 9 , wherein said infectious disease is caused by a bacterium.

14. The in vitro method according to claim 13 , wherein said infectious disease is caused by a bacterium belonging to the order Enterobacteriales.

Assignments (3)
CHANGE OF NAME Recorded Jun 17, 2022
From: UNIVERSITE DE PARIS
To: UNIVERSITÉ PARIS CITÉ
Reel/Frame 060530/0623 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 27, 2022
From: IVANOVA, SVILENA
To: METAFORA BIOSYSTEMS; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE; UNIVERSITÉ DE MONTPELLIER; UNIVERSITÉ DE PARIS
Reel/Frame 059751/0396 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 25, 2022
From: SITBON, MARC; PETIT, VINCENT; BATTINI, JEAN-LUC; COURGNAUD, VALÉRIE; GIOVANNINI, DONATELLA; LAZAAR, JAWIDA
To: METAFORA BIOSYSTEMS; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE; UNIVERSITÉ DE MONTPELLIER; UNIVERSITÉ DE PARIS
Reel/Frame 059741/0901 →
Priority Claims (1)
EP 18306319 · Oct 5, 2018 · regional
Continuity (1)
Related Publication 20220003782A1 · Jan 6, 2022
References Cited (31)
US 7842291B1 · Ruben et al. · 2010 [cited by applicant]
WO 2004096841A1 · 2004 [cited by applicant]
WO 2010079208A1 · 2010 [cited by applicant]
WO 2012035166A1 · 2012 [cited by applicant]
WO 2013060893A1 · 2013 [cited by applicant]
WO 2015110606A1 · 2015 [cited by applicant]
WO 2017085271A1 · 2017 [cited by applicant]
Whisstock et al., (Quarterly Reviews of Biophysics 2003, vol. 36 (3): 307-340,). [cited by examiner]
Witowski et al., (Biochemistry 38:11643-11650, 1999). [cited by examiner]
Kisselev L., (Structure, 2002, vol. 10: 8-9). [cited by examiner]
Devos et al., (Proteins: Structure, Function and Genetics, 2000, vol. 41: 98-107). [cited by examiner]
Mikayama et al. (Nov. 1993. Proc.Natl.Acad.Sci. USA, vol. 90 : 10056-10060). [cited by examiner]
International Search Report issued on Jan. 15, 2020, in connection with corresponding International Application No. PCT/EP2019/077078; 6 pages. [cited by applicant]
Wang, et al., “Human Placental Na+-dependent Multivitamin Transporter. Cloning, functional expression, gene structure, and chromosomal localization”, Journal of Biological Chemistry, May 21, 1999, vol. 274, No. 21, pp. … [cited by applicant]
Prasad, et al., “Cloning and Functional Expression of a cDNA Encoding a Mammalian Sodium-dependent Vitamin Transporter Mediating the Uptake of Pantothenate, Biotin, and Lipoate”, Journal of Biological Chemistry, Mar. 27… [cited by applicant]
Subramanian et al., “Mutations in SLC5A6 associated with brain, immune, bone, and intestinal dysfunction in a young child”, HHS Public Access Author Manuscript, Human Genetics, Feb. 2017, vol. 136, No. 2, 18 pp., doi: 1… [cited by applicant]
Quick et al., “The Sodium/Multivitamin Transporter: a Multipotent System with Therapeutic Implications”, HHS Public Access Author Manuscript, Vitamins and Hormones, 2015, vol. 98, 35 pp., doi: 10.1016/bs.vh.2014.12.003. [cited by applicant]
Ghosal et al., “ [cited by applicant]
Provenzani et al., “Global alterations in mRNA polysomal recruitment in a cell model of colorectal cancer progression to metastasis”, Carcinogenesis, Jul. 2006, vol. 27, No. 7, pp. 1323-1333 (11 pp.), doi: 10.1093/carci… [cited by applicant]
Sissung et al., “Identification of novel SNPs associated with risk and prognosis in patients with castration-resistant prostate cancer”, Pharmacogenomics, Dec. 2016, vol. 17, No. 18; pp. 1979-1986 (8 pp.), doi: 10.2217/… [cited by applicant]
Leithner et al., “TASK-1 Regulates Apoptosis and Proliferation in a Subset of Non-Small Cell Lung Cancers”, PLoS One, Jun. 13, 2016, vol. 11, No. 6, Article e0157453 (18 pp.), doi: 10.1371/journal.pone.0157453. [cited by applicant]
Pita et al., “Cell Cycle Deregulation and TP53 and RAS Mutations Are Major Events in Poorly Differentiated and Undifferentiated Thyroid Carcinomas”, Journal of Clinical Endocrinology and Metabolism, Mar. 2014, vol. 99, … [cited by applicant]
Vadlapudi et al., “Sodium Dependent Multivitamin Transporter (SMVT): A Potential Target for Drug Delivery”, HHS Public Access Author Manuscript, Current Drug Targets, Jun. 2012, vol. 13, No. 7, 21 pp., doi: 10.2174/1389… [cited by applicant]
Griffin et al., “Computer Analysis of Sequence Data, Parts I and II,” 1994, Humana Press, New Jersey, Journal of Evolutionary Biology, 7: 628-629. [cited by applicant]
Devereux et al., “A comprehensive set of sequence analysis programs for the VAX,” Nucleic Acids Research, Jan. 11, 1984, vol. 12, No. 1 Pt 1, pp. 387-395 (9 pp.), doi: 10.1093/nar/12.1part1.387. [cited by applicant]
Altschul et al., “Basic Local Alignment Search Tool”, Journal of Molecular Biology, Oct. 5, 1990, vol. 215, No. 3, pp. 403-410 (8 pp.), doi: 10.1016/S0022-2836(05)80360-2. [cited by applicant]
Krupovic et al., “Ortervirales: New Virus Order Unifying Five Families of Reverse-Transcribing Viruses”, Journal of Virology, May 29, 2018, vol. 92, No. 12, e00515-18 (5 pp.), doi: 10.1128/JVI.00515-18. [cited by applicant]
Schwantje et al., “Genetic defect of the sodium-dependent multivitamin transporter: A treatable disease, mimicking piotinidase deficiency”, JIMD Reports, May 28, 2019, vol. 48, No. 1, pp. 11-14 (4 pp.), doi: 10.1002/jmd… [cited by applicant]
Boonstra et al., “uPAR-targeted multimodal tracer for pre- and intraoperative imaging in cancer surgery”, Oncotarget, Jun. 10, 2015, vol. 6, No. 16, pp. 14260-14273 (14 pp.), doi: 10.18632/oncotarget.3680. [cited by applicant]
Watanabe et al., “Effects of biotin deficiency on embryonic development in mice”, Nutrition, Jan. 2009, vol. 25, No. 1, pp. 78-84 (7 pp.), doi: 10.1016/j.nut.2008.06.031. [cited by applicant]
Buys et al., “Genetic Changes in the Evolution of Multidrug Resistance for Cultured Human Ovarian Cancer Cells”, Genes Chromosomes & Cancer, Dec. 2007, vol. 46, No. 12, pp. 1069-1079 (11 pp.), doi: 10.1002/gcc.20492. [cited by applicant]